At Glasser, we have always been focused on delivering care that provides the best long-term patient outcomes. We track these outcomes – as well as complication and readmission rates – as part of our own performance and quality improvement program. Through our partnership with Altair Health, we are taking our efforts to a national level.
Now, we are one of the few centers in the country to participate in NeuroPoint Alliance’s pilot program. NeuroPoint Alliance is a nonprofit organization that transforms data into quality patient care through the collection, analysis and reporting of clinical data. Together with a small group of university practices, we track and pool outcomes-related data from brain tumor patients and develop data-driven treatment plans.
For our patients, this knowledge takes the treatment of brain tumors to the next level. For example, we can now begin to tailor a plan for a patient that has a brain tumor – as well as diabetes and high-blood pressure – all based on national outcomes.
To learn more about this, contact 973.993.7322.